On Thursday, the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) introduced the RAPID pathway for Medicare patients: expedited access to Class II and Class III Breakthrough Devices for timely, predictable access to the newest healthcare technologies.